{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:59:10Z","timestamp":1790805550366,"version":"4.1.0"},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T00:00:00Z","timestamp":1534982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Musculoskeletal manifestations of immune\u2010related adverse events (ir<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s) after checkpoint inhibitor immunotherapy for cancer remain incompletely characterized and poorly understood. A recently published case series suggested that immunotherapy\u2010induced arthritis is an aggressive process requiring high\u2010dose corticosteroids.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective chart review of all patients with musculoskeletal\u00a0ir<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s\u00a0first seen by one of the authors between 2014 and 2016. All patients had been treated for a malignancy with immune checkpoint inhibitors targeting <jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>\u20101 (nivolumab,\u00a0pembrolizumab), <jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>\u2010L1 (durvalumab), and\/or <jats:styled-content style=\"fixed-case\">CTLA<\/jats:styled-content>\u20104 (ipilimumab,\u00a0tremelimumab) at Memorial Sloan Kettering Cancer Center.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 10 patients with a mean \u00b1 <jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content> age of 63.2 \u00b1 9.7 years. Seven were treated with a combination of checkpoint inhibitors and 3 with\u00a0nivolumab\u00a0monotherapy. Four patients developed inflammatory polyarthritis, 4 oligoarthritis, and 2 tenosynovitis. Six were antinuclear antibody positive and 2 had anti\u2013cyclic citrullinated peptide antibodies. Mean \u00b1 <jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content> time from the first dose of immunotherapy until joint involvement was 6.3 \u00b1 4.3 months. All 10 patients were treated with systemic corticosteroids, but 6 of 10 required \u226420 mg per day of prednisone. Five patients received steroid\u2010sparing agents. Mean \u00b1 <jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content> time until resolution of joint symptoms after the last dose of immunotherapy was 9.2 \u00b1 6.1 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Musculoskeletal\u00a0ir<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s\u00a0can manifest as a rheumatoid arthritis\u2013like polyarthritis, oligoarthritis, tenosynovitis, or polymyalgia rheumatica. Musculoskeletal symptoms can last more than a year, but they can generally be managed with low to moderate doses of corticosteroids.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.23467","type":"journal-article","created":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T15:06:42Z","timestamp":1510326402000},"page":"362-366","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response"],"prefix":"10.1002","volume":"71","author":[{"given":"Melanie H.","family":"Smith","sequence":"first","affiliation":[{"name":"New York\u2010Presbyterian Hospital\/Weill Cornell Medicine New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne R.","family":"Bass","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine and Hospital for Special Surgery New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,8,23]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5256.1734"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv383"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209595"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23177"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209782"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6750"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8448"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27969"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.4368"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008002"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ16-0161"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.23467","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.23467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T17:33:26Z","timestamp":1759426406000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.23467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,23]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1002\/acr.23467"],"URL":"https:\/\/doi.org\/10.1002\/acr.23467","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,23]]},"assertion":[{"value":"2017-07-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}